Evidence map›Paper›PMID 42576844›Full record

ReviewSustainable microbiology2025

Impact and applications of cyclic di-GMP second messenger signaling in biotechnology and medicine.

Ute Römling

Abstract readReview
In one paragraph

Review in Sustainable microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ute RömlingDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0003-3812-6621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3',3'-cyclic diguanylate (cyclic di-GMP) and alternative cyclic di- and oligonucleotides are ancient highly conserved signaling molecules of bacteria and archaea, which can be present in metazoans up to humans. Their impact in fundamental behavioral modes and physiological and metabolic processes, the modular organization of their signaling cascades and the versatility and flexibility of their components in microbes in combination with their far-reaching effects including stimulation of the innate and adaptive immune response in humans makes these molecules and the respective signaling cascades promising targets in antibiofilm therapy, modulation of multicellularity and tools for treatment strategies and biotechnological applications. This review will thus describe the current state-of-the-art of applications and use as therapeutic targets of cyclic di- and oligonucleotides and the limitations and challenges in the application of those molecules and their use as targets. Future possibilities to successfully exploit those molecules and their signaling cascades equally as potential shortcomings are discussed.

Indexed as

bacterial biofilmsbiodegradationprobioticsremediationsynthetic biology

Identifiers

PMID42576844
PMCPMC13375341

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.